Results 81 to 90 of about 9,015 (261)

Study of Children Aged Under 2 Years Admitted With RSV at Four Australian Hospitals [2021–2022]

Journal of Paediatrics and Child Health, Volume 61, Issue 3, Page 482-490, March 2025.
ABSTRACT Aims Primary aim was to review severe acute respiratory infections (SARI) hospitalisations caused by respiratory syncytial virus (RSV) in children aged < 2 years in paediatric hospitals in Australia. Secondary aims included RSV subtyping, assessing RSV seasonality and contributing to the World Health Organisation's RSV surveillance programme ...
Nigel W. Crawford, Annette Alafaci, Julia E. Clark, Joshua R. Francis, Christopher C. Blyth, Catherine Pienaar, Cara Minney‐Smith, Sonia Dougherty, Anjalee Panditha, Laura Francis, Ian G. Barr   +10 more
wiley   +1 more source

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey

The Turkish Journal of Pediatrics, 2012
The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel, Banu Mutlu, Sumru Kavurt, Ahmet Yağmur Baş, Nihal Demirel, Mesut Akyol, Omer Erdeve, Uğur Dilmen   +7 more
doaj  

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro

The Turkish Journal of Pediatrics
Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic, Ljubinka Dragas, Drasko Nikcevic, Jasmina Lekic, Ana Dedic, Ljiljana Sulovic   +5 more
doaj   +1 more source

Trends in Proportions of Respiratory Syncytial Virus Infections Among Reported Respiratory Tract Infection Cases in Children Aged 0 to 5 Years in Western Pacific and Southeast Asia Regions: A Systematic Review and Meta‐Analysis

Influenza and Other Respiratory Viruses, Volume 19, Issue 2, February 2025.
ABSTRACT Background Respiratory syncytial virus (RSV) is an important cause of bronchiolitis and pneumonia in children globally. This study aimed to incorporate new data to update estimates of RSV burden in children through 5 years of age in Western Pacific and Southeast Asia Regions.
Sangshin Park, Hyelan Lee, Jung Yoon Park, Sujin Choi, Hyun Jung Kim, Lorenzo Bertizzolo, Young Hwa Lee, Young June Choe   +7 more
wiley   +1 more source

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

International Journal of General Medicine, 2018
Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj  

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

BMC Research Notes, 2012
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V, Baibarina Elena N, Degtiareva Elena A, Keshishyan Elena S, Lobzin Yurii V, Namazova-Вaranova Leyla S, Prodeus Andrey P, Gudkov Konstantin M, Kruglova Anna I, Schulz Gregory A, Notario Gerard F   +10 more
doaj   +1 more source

Impact of Viral Lower Respiratory Tract Infection (LRTI) in Early Childhood (0–2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health (NIH) Workshop Summary

Pediatric Pulmonology, Volume 60, Issue 1, January 2025.
ABSTRACT Viral lower respiratory tract infections (LRTI) are ubiquitous in early life. They are disproportionately severe in infants and toddlers (0–2 years), leading to more than 100,000 hospitalizations in the United States per year. The recent relative resilience to severe Coronavirus disease (COVID‐19) observed in young children is surprising ...
Hitesh Deshmukh, Jeffrey Whitsett, William Zacharias, Sing Sing Way, Fernando D. Martinez, Joseph Mizgerd, Gloria Pryhuber, Namasivayam Ambalavanan, Leonard Bacharier, Aruna Natarajan, Robert Tamburro, Sara Lin, Adrienne Randolph, Gustavo Nino, Asuncion Mejias, Octavio Ramilo, The NIH Workshop Participants of the ‘Viral Lower Respiratory Tract Infections in Infancy and Early Childhood‐Immunological and Developmental Aspects’, N. Ambalavanan, Leonard B. Bacharier, Gustavo Nino, Bria M. Coates, Hitesh Deshmukh, Melody Duvall, Matthew Frieman, James Gern, Sarah Gilpin, Thomas B. Kepler, Michele Kong, Richard Locksley, Thomas Mariani, Fernando Martinez, Sharon McGrath‐Marrow, Asuncion Mejias, Lisa Miller, Joseph Mizgerd, Wayne Morgan, Peter Mourani, Gloria Pryhuber, Octavio Ramilo, Adrienne Randolph, Fariba Rezaee, Jason Rock, Jeffrey (Jeff) Whitsett, Sing Sing Way, William Zacharias, Neil Aggarwal, Marishka Brown, Matthew Craig, James Kiley, Sonnie Kim, Marrah Lachowicz‐Scroggins, Sara Lin, Valerie Maholmes, Aruna Natarajan, Robert Tamburro   +54 more
wiley   +1 more source

palivizumab and the importance of cost effectiveness

BMJ, 2009
Prioritising scarce NHS resources is difficult and contentious. Alison Teale , Sanjeev Deshpande , and Amanda Burls discuss the issues surrounding cost effectiveness decisions in the health service and the processes used by a commissioning team in the West ...
Teale, A, Deshpande, S, Burls, A
openaire   +2 more sources

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention [PDF]

, 2012
Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein ...
C. Palomo, Connors, D. Luque, Delgado, Falsey, Glezen, Graham, Groothuis, J. A. Melero, K. Chappell, KIM, Lamb, Lopez, M. C. Terron, M. Magro, M. Vazquez, McLellan, Nair, O. Cano, Prince, Sastre, Stott, The IMpact-RSV Study Group, Toiron, V. Mas, Yin   +25 more
core   +2 more sources

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]

Саратовский научно-медицинский журнал, 2016
Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М., Gavrilova E.S., Borisova А.А., Pazgalyova N.V., Panina O.S., Chernenkov Yu.V.   +5 more
doaj